Genedrive PLC Directorate Change (2405K)

TIDMGDR

RNS Number : 2405K

Genedrive PLC

09 April 2018

For release: 9 April 2018

genedrive plc ("genedrive" or the "Company")

genedrive appoints Tom Lindsay as Non-Executive Director

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, today announces that it has appointed Tom Lindsay as a Non-Executive Director with immediate effect.

Tom has 35 years of global sales and marketing experience in the diagnostics sector. He most recently worked for Alere Inc. in Africa for 11 years before retiring in 2017. At Alere he held a range of executive posts including President of Africa, President Commercial Operations for Africa, and Business Development Director for Africa; and led the introduction and successful commercialisation of a number of key HIV screening and HIV patient management point of care diagnostics technologies.

Prior to joining Alere Inc., Tom held senior commercial roles at Trinity Biotech (Ireland) including Marketing and Sales Director (Global) and Business Development Director for Africa, Middle East and India. Trinity Biotech specialises in the development, manufacture and marketing of diagnostic test kits.

Tom studied Microbiology at Glasgow Caledonian University and completed a National Diploma in Microbiology at the South African Institute of Medical Research in Johannesburg, South Africa.

Ian Gilham, Non-Executive Chairman of genedrive, said: "Tom has exceptionally strong experience in commercialising diagnostics in Africa and other low and middle income markets. We look forward to working with him as we continue to deliver on the opportunities presented by our Genedrive(R) HCV ID test, which is the first decentralised test to market, and by the Genedrive(R) platform more widely."

Tom Lindsay said: "The simplicity, low-cost, speed and versatility of the Genedrive(R) platform represent significant strengths for decentralised molecular diagnostics. I am excited to join the Board and about the prospects for Genedrive(R) across multiple indications and markets."

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

Full name and age: Thomas Lindsay (aged 60)

Tom Lindsay does not currently hold any shares in genedrive plc.

Current Directorships or Partnerships:

None

Previous Directorships or Partneships in the last five years:

Alere Healthcare Pty Ltd

Pantech Pty Ltd

Alere Nigeria Ltd

Vision Biotech Pty Ltd

No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.

- Ends -

For further details please contact:

 
 genedrive plc                         [phone] 
 David Budd: CEO 
 Matthew Fowler: CFO 
 
 Peel Hunt LLP                         [phone] 
 James Steel 
 Oliver Jackson 
 
 Consilium Strategic Communications    [phone] 
 Chris Gardner 
 Matthew Neal 
 Laura Thornton 
 [e-mail] 
 
 Stanford Capital Partners 
  Limited                              [phone] 
 Patrick Claridge 
 

Notes to Editors

About genedrive plc

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive(R) platform and MTB/RIF assay has been launched in India and a Genedrive(R) HCV test has received CE-IVD Certification and has been launched in Africa. genedrive has distribution agreements with subsidiaries of Sysmex Corporation for the distribution of the Genedrive(R) platform in the EMEA and Asia Pacific regions, and with ARKRAY Healthcare pvt Ltd for the distribution of the Genedrive(R) HCV ID Kit and Genedrive(R) platform in India.

Further details can be found at: www.genedriveplc.com and www.genedrive.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAUKRWRWOASRRR

(END) Dow Jones Newswires

April 09, 2018 04:06 ET (08:06 GMT)